How to face the aging world – lessons from dementia research

A continuous rise in life expectancy has led to an increase in the number of senior citizens, now amounting to a fifth of the global population, and to a dramatic increase in the prevalence of diseases of the elderly. This review discusses the threat of dementia, a disease that imposes enormous financial burden on health systems and warrants efficient therapeutic solutions. What we learned from numerous failed clinical trials is that we have to immediately take into account two major elements: early detection of dementia, much before the onset of symptoms, and personalized (precision) medicine treatment approach. We also discuss some of the most promising therapeutic directions, including stem cells, exosomes, electromagnetic fields, and ozone.

[1]  K. Blennow,et al.  Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration , 2020, Neurobiology of Disease.

[2]  Q. Tu,et al.  miR-340 reduces accumulation of amyloid-β through targeting BACE1 (β-site amyloid precursor protein cleaving enzyme 1) in Alzheimer' s disease. , 2020, Current neurovascular research.

[3]  Yunjia Chen,et al.  β-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade , 2020, Science Translational Medicine.

[4]  V. Libri,et al.  Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations , 2020, JAMA neurology.

[5]  John P. Williams,et al.  Ozone Inhibits APP/Aβ Production and Improves Cognition in an APP/PS1 Transgenic Mouse Model , 2019, Neuroscience.

[6]  M. Phillips Fasting as a Therapy in Neurological Disease , 2019, Nutrients.

[7]  J. Wiltfang,et al.  CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[8]  Sudha Seshadri,et al.  Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis , 2019, BMJ.

[9]  D. Mitrečić,et al.  Molecular mechanisms of microglia- and astrocyte-driven neurorestoration triggered by application of electromagnetic fields , 2019, Croatian medical journal.

[10]  R. Pochet,et al.  A call for unification: how to defragment the human brain, medical professions, and national strategies? , 2019, Croatian medical journal.

[11]  J. Trojanowski,et al.  Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology , 2019, Molecular Neurodegeneration.

[12]  A. Fagan,et al.  Reduced non–rapid eye movement sleep is associated with tau pathology in early Alzheimer’s disease , 2019, Science Translational Medicine.

[13]  J. Boeke,et al.  LINE-1 derepression in senescent cells triggers interferon and inflammaging , 2018, Nature.

[14]  D. Chaudhury,et al.  Modeling of inhomogeneous electromagnetic fields in the nervous system: a novel paradigm in understanding cell interactions, disease etiology and therapy , 2018, Scientific Reports.

[15]  K. Blennow,et al.  Biomarkers for Alzheimer's disease: current status and prospects for the future , 2018, Journal of internal medicine.

[16]  B. Kennedy,et al.  Development, Application, and Results from a Precision-medicine Platform that Personalizes Multi-modal Treatment Plans for Mild Alzheimer’s Disease and At-risk Individuals , 2018, Current aging science.

[17]  Laila E. Amin Biological assessment of ozone therapy on experimental oral candidiasis in immunosuppressed rats , 2018, Biochemistry and biophysics reports.

[18]  L. Fassina,et al.  Low-Frequency Pulsed Electromagnetic Field Is Able to Modulate miRNAs in an Experimental Cell Model of Alzheimer's Disease , 2017, Journal of healthcare engineering.

[19]  D. Kapogiannis,et al.  Insulin resistance in Alzheimer's disease , 2017, Translational research : the journal of laboratory and clinical medicine.

[20]  D. Barrett,et al.  Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice , 2017, Brain : a journal of neurology.

[21]  T. Oosterkamp,et al.  Human-brain ferritin studied by muon spin rotation: a pilot study , 2017, Journal of physics. Condensed matter : an Institute of Physics journal.

[22]  H. Aldskogius,et al.  Murine neural crest stem cells and embryonic stem cell‐derived neuron precursors survive and differentiate after transplantation in a model of dorsal root avulsion , 2017, Journal of tissue engineering and regenerative medicine.

[23]  S. Gajović,et al.  Neural stem cells from mouse strain Thy1 YFP-16 are a valuable tool to monitor and evaluate neuronal differentiation and morphology , 2016, Neuroscience Letters.

[24]  Dale E. Bredesen,et al.  Reversal of cognitive decline in Alzheimer's disease , 2016, Aging.

[25]  T. Montine,et al.  Precision Medicine: Clarity for the Complexity of Dementia. , 2016, The American journal of pathology.

[26]  D. Bredesen Inhalational Alzheimer's disease: an unrecognized—and treatable—epidemic , 2016, Aging.

[27]  D. Selkoe,et al.  C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death , 2015, The Journal of Neuroscience.

[28]  Lars Bäckman,et al.  A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial , 2015, The Lancet.

[29]  Hyung-Do Choi,et al.  1950 MHz Electromagnetic Fields Ameliorate Aβ Pathology in Alzheimer’s Disease Mice , 2015, Current Alzheimer research.

[30]  S. Kourembanas Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. , 2015, Annual review of physiology.

[31]  S. Rossi,et al.  Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) , 2014, Clinical Neurophysiology.

[32]  Dale E. Bredesen,et al.  Reversal of cognitive decline: A novel therapeutic program , 2014, Aging.

[33]  S. Golaszewski,et al.  Transcranial magnetic stimulation (TMS)/repetitive TMS in mild cognitive impairment and Alzheimer's disease , 2014, Acta neurologica Scandinavica.

[34]  K. Zilles,et al.  Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia , 2014, Molecular Psychiatry.

[35]  N. Tyagi,et al.  Exosomes: Mediators of Neurodegeneration, Neuroprotection and Therapeutics , 2014, Molecular Neurobiology.

[36]  G. Müller,et al.  Microvesicles/exosomes as potential novel biomarkers of metabolic diseases , 2012, Diabetes, metabolic syndrome and obesity : targets and therapy.

[37]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[38]  M. Nitsche,et al.  Physiological Basis of Transcranial Direct Current Stimulation , 2011, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[39]  B. Winblad,et al.  Homocysteine and holotranscobalamin and the risk of Alzheimer disease , 2010, Neurology.

[40]  R. Wennberg,et al.  A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease , 2010, Annals of neurology.

[41]  Graça Raposo,et al.  Exosomes--vesicular carriers for intercellular communication. , 2009, Current opinion in cell biology.

[42]  K. Blennow,et al.  The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. , 2008, Clinical chemistry.

[43]  F. LaFerla,et al.  Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: A role for intraneuronal amyloid , 2007, Neuroscience & Biobehavioral Reviews.

[44]  G. Raposo,et al.  Exosomes: a common pathway for a specialized function. , 2006, Journal of biochemistry.

[45]  Yoshikazu Ugawa,et al.  Long‐term effect of motor cortical repetitive transcranial magnetic stimulation induces , 2004 .

[46]  M. Nitsche,et al.  Pharmacological approach to the mechanisms of transcranial DC-stimulation-induced after-effects of human motor cortex excitability. , 2002, Brain : a journal of neurology.

[47]  N. Mokhov,et al.  Muons versus hadrons for radiotherapy , 1999, Proceedings of the 1999 Particle Accelerator Conference (Cat. No.99CH36366).

[48]  Hae-June Lee,et al.  MHz Electromagnetic Fields Ameliorate A β Pathology in Alzheimer ’ s Disease Mice , 2015 .

[49]  Q. Mu,et al.  Repetitive Transcranial Magnetic Stimulation as an Alternative Therapy for Cognitive Impairment in Alzheimer's Disease: A Meta-Analysis. , 2015, Journal of Alzheimer's disease : JAD.

[50]  D. Bohl,et al.  Genetically modified stem cells for the treatment of neurological diseases. , 2012, Frontiers in bioscience.

[51]  Jun Tan,et al.  Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice. , 2010, Journal of Alzheimer's disease : JAD.

[52]  G. Parmiani,et al.  Tumour-released exosomes and their implications in cancer immunity , 2008, Cell Death and Differentiation.

[53]  V. Bocci OZONE: A new medical drug , 2005 .